The domestic pharmaceutical and biotech sectors are once again drawing attention amid growing expectations for technology export momentum in the second half of the year. In the market, investors are focusing not only on companies that have already secured large-scale contracts but also on those with the potential for new technology transfers.

The industry cites research and development (R&D) achievements and the possibility of collaborations with global pharmaceutical companies as the key criteria for recent biotech investments. In particular, for companies that have produced strong clinical results, expectations regarding the scale of technology exports are rapidly growing, drawing investor attention to firms such as Alteogen, D&D Pharmatech, and ABL Bio.

According to industry assessments, numerous global pharmaceutical companies are showing deep interest in related technologies, and there are observations that additional business opportunities may continue beyond already signed contracts. The securities sector is also raising the possibility that future technology export deal sizes could be substantial. However, some caution that the actual conclusion and scale of contracts depend on future negotiation outcomes, necessitating a prudent approach.

A market participant stated, "In the biotech sector, potential often drives stock prices," adding, "Clinical results and interest from global pharmaceutical companies will act as key variables going forward."

Accordingly, analysts advise closely monitoring market trends and remaining highly alert to upcoming Monday's stock price movements.

[This article introduces various opinions and investment sentiment circulating in the market and does not constitute a recommendation to invest in any specific stock. Investors are solely responsible for their investment decisions. Written with AI assistance.]